ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

12,079Medicare Part D Prescriptions Filled, Including Refills
$1.23M Total Retail Price of All Prescriptions
800 Patients Receiving at Least One Drug in Part D
10%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
RISPERIDONE 1,080 154
BENZTROPINE MESYLATE 878 69 R
TRAZODONE HCL 845 79
CITALOPRAM HBR 804 85
DIVALPROEX SODIUM 526 26
ZOLPIDEM TARTRATE 514 59
BUPROPION HCL SR 480 49
FLUOXETINE HCL 386 44
LITHIUM CARBONATE 344 34
QUETIAPINE FUMARATE 342 28
BUSPIRONE HCL 337 31
SERTRALINE HCL 289 49
GABAPENTIN 286 31
OLANZAPINE 274 28
ABILIFY 267 44
HYDROXYZINE PAMOATE 265 21 R
MIRTAZAPINE 251 54
PROPRANOLOL HCL 191 0
HALOPERIDOL 184 0
VENLAFAXINE HCL ER 183 26
DIVALPROEX SODIUM ER 181 23
LOXAPINE 178 22
INVEGA SUSTENNA 172 13
PAROXETINE HCL 172 24
SEROQUEL 147 0
CARBAMAZEPINE 139 0
LAMOTRIGINE 138 12
RISPERDAL CONSTA 136 28
CLOZAPINE 133 0
SEROQUEL XR 119 14
AMITRIPTYLINE HCL 112 11 R
PERPHENAZINE 112 0
CYMBALTA 97 0
TRIHEXYPHENIDYL HCL 93 0 R
VALPROIC ACID 90 11
HALOPERIDOL DECANOATE 100 78 0
DOXEPIN HCL 77 13
OLANZAPINE ODT 74 11
BUPROPION XL 72 0
HYDROXYZINE HCL 58 0 R
CHLORPROMAZINE HCL 58 0
FLUPHENAZINE HCL 55 0
ESCITALOPRAM OXALATE 53 11
ZIPRASIDONE HCL 51 0
AMANTADINE 51 0
INVEGA 51 0
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.